A BILL FOR AN ACT to amend the Indiana Code concerning professions and occupations.
Summary
HB 1129 makes a broad set of changes to Indiana law governing advanced practice registered nurses (APRNs), with the central change being the removal of the statutory requirement that APRNs maintain a practice agreement with a collaborating physician in order to practice. The bill also removes related language requiring APRNs to operate under a collaborative practice agreement or hospital-granted privileges, and it repeals the existing audit process tied to APRN practice agreements. In addition, it updates several sections of the Indiana Code to reflect the new framework and makes conforming changes across health, licensing, and controlled-substance statutes.
The bill also expands certain APRN authorities in specific clinical settings. It allows APRNs with prescriptive authority to prescribe a Schedule II controlled substance for weight reduction or obesity treatment, while preserving existing requirements for controlled-substance prescribing and obesity-treatment safeguards. It also updates Medicaid and public health provisions so APRNs can be recognized as providers in community mental health, substance use, and HIV-testing contexts, subject to scope-of-practice limits and other conditions stated in the bill. The effective date for the changes is July 1, 2026.
Impact
HB 1129 would substantially revise the regulatory structure for APRNs in Indiana by eliminating the practice-agreement requirement and associated audit provisions, while preserving some scope-of-practice and prescribing limits in other parts of law. It amends statutes affecting Medicaid reimbursement, opioid treatment programs, HIV testing, stimulant prescribing for children, nursing board authority, and controlled-substance treatment for obesity, and it repeals a related immunity statute tied to the old audit system. The bill would affect APRNs, collaborating physicians, hospitals, Medicaid providers, opioid treatment programs, and patients receiving mental health, substance use, HIV, or weight-loss treatment services.
Sentiment
The bill text and available context suggest a generally pro-APRNs direction, with the main thrust being professional autonomy and reduced administrative oversight. Because there are no committee transcripts or recorded votes provided, there is no direct evidence of floor or committee sentiment in the materials supplied. Based on the bill’s structure, the overall tone appears supportive of expanding APRN practice authority while retaining targeted safeguards in prescribing and treatment settings.
Contention
The most likely point of contention is the removal of the collaborating-physician practice agreement requirement, which would be a significant change for physician oversight and existing APRN regulatory arrangements. Related concerns may include the repeal of the APRN audit process and the expansion of APRN prescribing authority to include Schedule II controlled substances for weight reduction or obesity treatment. Another possible area of debate is whether the bill sufficiently protects patient safety in opioid treatment, pediatric stimulant prescribing, and controlled-substance use, versus whether it unnecessarily limits access to care by keeping some collaboration and scope restrictions in place.